TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ANNX

Annexon Inc

Healthcare · Biotechnology

4.20$ +6.1% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Annexon Inc (ANNX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.4% of the shares are freely tradable; institutional investors hold 102.7%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 102.7%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 86.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 17.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 190Mio.

Largest Shareholders

Institutions

Institutions ANNX
Name Stake (%) Shares Change (%) Date
Redmile Group, LLC 6.26 11,869,877 -18.4 06/30/2026
BlackRock Inc 5.77 10,938,509 +22.1 03/31/2026
FMR Inc 5.61 10,635,648 +4.0 03/31/2026
Bvf Inc 4.59 8,698,173 -4.7 03/31/2026
State Street Corp 3.65 6,919,255 +48.7 03/31/2026
Vanguard Capital Management, LLC 3.14 5,956,589 +0.0 03/31/2026
Bain Capital Life Sciences Investors, LLC 2.75 5,212,674 -0.7 03/31/2026
Bellevue Group AG 2.72 5,157,290 +0.0 03/31/2026

Funds

Funds ANNX
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 3.47 6,578,625 -1.1 08/31/2026
Fidelity Select Biotechnology 3.26 6,174,755 +0.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?